Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 11/20 | 0.55 |
| ▸ | S1PR3 | Q99500 | 11/20 | 0.55 |
| ▸ | S1PR4 | O95977 | 5/20 | 0.55 |
| ▸ | S1PR5 | Q9H228 | 5/20 | 0.55 |
| ▸ | PPARA | Q07869 | 9/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4631277 | 0.89 | S1PR1 (0.52) | S1PR1S1PR3S1PR4S1PR5PPARA | |
| SCHEMBL4664502 | 0.87 | S1PR1 (0.53) | S1PR1S1PR3S1PR4S1PR5PPARA | |
| SCHEMBL4982748 | 0.84 | S1PR1 (0.63) | S1PR1S1PR3S1PR4S1PR5PPARA | |
| SCHEMBL4982745 | 0.84 | S1PR1 (0.63) | S1PR1S1PR3S1PR4S1PR5PPARA | |
| SCHEMBL4979835 | 0.82 | S1PR1 (0.62) | S1PR1S1PR3S1PR4S1PR5PPARA | |
| SCHEMBL4724985 | 0.82 | S1PR1 (0.62) | S1PR1S1PR3S1PR4S1PR5PPARA | |
| SCHEMBL4980002 | 0.82 | S1PR4 (0.62) | S1PR1S1PR3S1PR4S1PR5 | |
| SCHEMBL5174049 | 0.81 | S1PR1 (0.59) | S1PR1S1PR3S1PR4S1PR5PPARA | |
| SCHEMBL4986288 | 0.81 | S1PR1 (0.63) | S1PR1S1PR3S1PR4S1PR5PPARA | |
| SCHEMBL4983634 | 0.80 | S1PR1 (0.60) | S1PR1S1PR3S1PR4S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080064662-A1 | Methods and compositions for modulating sphingosine -1- phosphate (S1P) receptor activity | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2008-03-13 | — | — | US | disclosed |
| US-7241812-B2 | Methods and compositions for modulating sphingosine-1-phosphate (S1P) receptor activity | PRAECIS PHARMACEUTICALS, INC. (US) | 2007-07-10 | — | — | US | disclosed |
| EP-1781595-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR ACTIVITY | Praecis Pharmaceuticals Inc. (US) | 2007-05-09 | — | — | EP | disclosed |
| US-20060223866-A1 | Methods and compositions for modulating sphingosine-1-phosphate (S1P) receptor activity | PRAECIS PHARMACEUTICALS, INC. (US) | 2006-10-05 | — | — | US | disclosed |
| US-20060135786-A1 | Methods and compositions for modulating sphingosine-1-phosphate (S1P) receptor activity | PRAECIS PHAMACEUTICALS, INC. (US) | 2006-06-22 | — | — | US | disclosed |
| WO-2006020951-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR ACTIVITY | PRAECIS PHARMACEUTICALS, INC. (US) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064662-A1 | Methods and compositions for modulating sphingosine -1- phosphate (S1P) receptor activity | S1PR1, S1PR2, S1PR3 | S1PR1 1/4885S1PR3 3/4885S1PR4 5/4885 |
| US-20060223866-A1 | Methods and compositions for modulating sphingosine-1-phosphate (S1P) receptor activity | S1PR1, S1PR2, S1PR3 | S1PR1 1/4885S1PR3 3/4885S1PR4 5/4885 |
| US-20060135786-A1 | Methods and compositions for modulating sphingosine-1-phosphate (S1P) receptor activity | S1PR1, S1PR2, S1PR3 | S1PR1 1/4885S1PR3 3/4885S1PR4 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.